Journal Mobile Options
Table of Contents
Vol. 12, No. 2, 2001
Issue release date: March–April 2001
Dement Geriatr Cogn Disord 2001;12:167–170
(DOI:10.1159/000051252)

Circulating Leptin Levels and Weight Loss in Alzheimer’s Disease Patients

Power D.A. · Noel J. · Collins R. · O’Neill D.
aDepartment of Clinical Geratology, Radcliffe Infirmary, Oxford, UK; bDepartment of Medicine for the Elderly, Mater Misericordiae Hospital, and cDepartment of Age-Related Health Care, Adeleaide, Meath and National Childrens Hospital, Tallaght, Dublin, Ireland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Weight loss is common in Alzheimer’s disease (AD) and is predictive of mortality. Leptin, an adipocyte-derived peptide hormone is implicated in the regulation of satiety and energy expenditure. It acts on the hypothalamus to suppress appetite and increase energy expenditure. We undertook this study to determine if inappropriately elevated leptin levels play a role in AD-associated weight loss. Serum leptin levels of 8 patients in each of the following groups were determined: (1) AD, body mass index (BMI) >25; (2) AD, BMI <20; (3) non-Alzheimer’s (vascular) dementia (VaD), BMI >25, and (4) VaD, BMI <20. Mean serum leptin levels were significantly lower in below-appropriate-weight patients (both AD and VaD) than in appropriate-weight controls. Below-appropriate-weight AD patients had a significantly lower mean serum leptin concentration than appropriate-weight VaD controls. Weight loss is a feature of AD. Inappropriately elevated leptin levels do not appear to be implicated. Indeed, we have shown that the afferent limb of the leptin feedback loop is intact in below-appropriate-weight AD patients and suggest hypothalamic dysfunction may underlie this feature.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–1342.
  2. O’Neill D, McKiernan M, Gibney M, Walsh JB, Coakley D: Diet and anthropometric measures in mild to moderate senile dementia of the Alzheimer type. J Hum Nutr Diet 1990;3:175–179.
  3. White H, Pieper C, Schmader K, Fillenbaum G: Weight change in Alzheimer’s disease. J Am Geriatr Soc 1996;44:265–272.
  4. Franklin Ca, Karkeck J: Weight loss and senile dementia in an institutionalised elderly population. J Am Diet Assoc 1989;89:790–792.

    External Resources

  5. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME: The biology of leptin: A review. J Anim Sci 1998;76:1405–2014.
  6. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Working Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  8. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
  9. White H, Pieper C, Schmader K: The association of weight change in Alzheimer’s disease with severity of disease and mortality: A longitudinal analysis. J Am Geriatr Soc 1998;46:1223–1227.
  10. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC: Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996;44:1147–1152.
  11. Sing VK, Guthikonda P: Circulating cytokines in Alzheimer’s Disease. J Psychiatr Res 1997;31:657–660.
  12. Kirchgessner TG, Uysal KT, Weisbrock SM, Marino MW, Hotamisligil GS: Tumor necrosis factor alpha contributes to obesity-related hyperleptinaemia by regulating leptin release from adipocytes. J Clin Invest 1997;100:2777–2782.
  13. Cederholm T, Arner P, Palmblad J: Low circulating leptin levels in protein-energy malnourished chronically ill elderly patients. J Intern Med 1997;242:377–382.
  14. Rosenbaum M, Nicholson M, Hirsch J, Murphy E, Chu F, Leibel RL: Effects of weight change on plasma leptin concentrations and energy expenditure. J Clin Endocrinol Metab 1997;82:3647–3654.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00